Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies.
M D Smirnov, … , N L Esmon, C T Esmon
M D Smirnov, … , N L Esmon, C T Esmon
Published January 1, 1995
Citation Information: J Clin Invest. 1995;95(1):309-316. https://doi.org/10.1172/JCI117657.
View: Text | PDF
Research Article Article has an altmetric score of 10

On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies.

  • Text
  • PDF
Abstract

Phosphatidylethanolamine (PE) is an important membrane component for supporting activated protein C anticoagulant activity but has little influence on prothrombin activation. This difference constitutes a potential mechanism for selective inhibition of the protein C anticoagulant pathway by lupus anticoagulants and/or antiphospholipid antibodies. In this study, we demonstrate that the presence of PE augments lupus anticoagulant activity. In the plasma of some patients with lupus anticoagulants, activated protein C anticoagulant activity is more potently inhibited than prothrombin activation. As a result, in the presence of activated protein C and PE, these patient plasmas clot faster than normal plasma. Patients with minimal lupus anticoagulant activity are identified whose plasma potently inhibits activated protein C anticoagulant activity. This process is also PE dependent. In three patient plasmas, these phenomena are shown to be due to immunoglobulins. The PE requirement in the expression of activated protein C anticoagulant activity and the PE dependence of some antiphospholipid antibodies provide a mechanistic basis for the selective inhibition of the protein C pathway. Inhibition of activated protein C function may be a common mechanism contributing to increased thrombotic risk in certain patients with antiphospholipid antibodies.

Authors

M D Smirnov, D T Triplett, P C Comp, N L Esmon, C T Esmon

×

Total citations by year

Year: 2022 2017 2015 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1960 Total
Citations: 1 4 1 1 1 4 1 5 3 2 7 3 2 6 5 4 10 5 9 7 11 1 1 94
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (94)

Title and authors Publication Year
Anti-phospholipid antibodies are elevated and functionally active in chronic rhinosinusitis with nasal polyps.
Eide JG, Wu J, Stevens WW, Bai J, Hou S, Huang JH, Rosenberg J, Utz P, Shintani-Smith S, Conley DB, Welch KC, Kern RC, Hulse KE, Peters AT, Grammer LC, Zhao M, Lindholm P, Schleimer RP, Tan BK
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 2022
Diagnosis and management of the antiphospholipid syndrome
S Chaturvedi, KR McCrae
Blood Reviews 2017
Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers
S Chaturvedi, KR McCrae
Current Rheumatology Reports 2017
Lupus
WA Khan
Lupus 2017
Early endosome as a pathogenic target for antiphosphatidylethanolamine antibodies
S Hou, H Fölsch, K Ke, JC Mills, R Ramsey-Goldman, M Zhao
Proceedings of the National Academy of Sciences 2017
Seronegative Antiphospholipid Syndrome with Anti-phosphatidylethanolamine Antibody in a Boy
T Asano, H Narazaki, K Kaizu, K Kuwabara, O Fujino, Y Itoh
Journal of Nippon Medical School 2015
Synergistic Thrombotic Risk of Antibodies Against Phosphatidylserine and Prothrombin and β-2-Glycoprotein I
H Kim, JE Kim, SM Hwang, HR Lee, KS Han, HK Kim
Clinical and Applied Thrombosis/Hemostasis 2013
Modeling of human factor Va inactivation by activated protein C
MC Bravo, T Orfeo, KG Mann, SJ Everse
BMC Systems Biology 2012
Influence of chronic inflammation and autoimmunity on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients
W Plazak, M Pasowicz, M Kostkiewicz, J Podolec, L Tomkiewicz-Pajak, J Musial, P Podolec
Inflammation Research 2011
Advances in Immunology
E Pinaud, M Marquet, R Fiancette, S Péron, C Vincent-Fabert, Y Denizot, M Cogné
Advances in Immunology Volume 110 2011
Cognitive dysfunction and white matter abnormalities in antiphospholipid syndrome
D Erkan, E Kozora, MD Lockshin
Pathophysiology 2011
Antiphospholipid antibody syndrome—an overview
C Sridevi, PK Raju
Journal of Indian College of Cardiology 2011
Antiphospholipid antibodies and the protein C pathway
SS Pierangeli, ML Bertolaccini, MA Khamashta, RT Urbanus, B Laat
Lupus 2010
Basic mechanisms and pathogenesis of venous thrombosis
CT Esmon
Blood Reviews 2009
Mechanisms of antiphospholipid-induced thrombosis: Effects on the protein C system
D Wahl, A Membre, C Perret-Guillaume, V Regnault, T Lecompte
Current Rheumatology Reports 2009
Lantibiotics as probes for phosphatidylethanolamine
M Zhao
Amino Acids 2009
Phosphatidylethanolamine at the endothelial surface of aortic flow dividers
Z Li, CW Wells, CT Esmon, M Zhao
Journal of Thrombosis and Haemostasis 2009
Phosphatidylethanolamine at the Luminal Endothelial Surface—Implications for Hemostasis and Thrombotic Autoimmunity
Z Li, CW Wells, PE North, S Kumar, CB Duris, JA McIntyre, M Zhao
Clinical and Applied Thrombosis/Hemostasis 2009
Clinical Immunology
DB Kuhns
Clinical Immunology 2008
Further evidence of false negative screening for lupus anticoagulants
GW Moore, A Henley, CK Greenwood, S Rangarajan
Thrombosis Research 2008
The Relationship Between the Antiphospholipid Syndrome and Heparin-Induced Thrombocytopenia
DA Hoppensteadt, JM Walenga
Hematology/Oncology Clinics of North America 2008
Activated protein C resistance determined with a thrombin generation-based test is associated with thrombotic events in patients with lupus anticoagulants
S Liestøl, PM Sandset, MC Mowinckel, F Wisløff
Journal of Thrombosis and Haemostasis 2007
Metabolic and molecular aspects of ethanolamine phospholipid biosynthesis: the role of CTP:phosphoethanolamine cytidylyltransferase (Pcyt2)
M Bakovic, MD Fullerton, V Michel
Biochemistry and Cell Biology 2007
[Pathogenesis of the antiphospholipid syndrome]
JL Pasquali, V Poindron, AS Korganow, T Martin
Presse medicale (Paris, France : 1983) 2006
The Antiphospholipid Syndrome: What are We Really Measuring? How do We Measure it? And How do We Treat it?
TL Ortel
Journal of Thrombosis and Thrombolysis 2006
A human monoclonal antiprothrombin antibody is thrombogenic in vivo and upregulates expression of tissue factor and E-selectin on endothelial cells
M Vega-Ostertag, X Liu, H Kwan-Ki, P Chen, S Pierangeli
British Journal of Haematology 2006
Detection of acquired resistance to activated protein C associated with antiphospholipid antibodies using a novel clotting assay
C Gardiner, H Cohen, A Jenkins, SJ Machin, IJ Mackie
Blood Coagulation & Fibrinolysis 2006
Placental Thrombosis and Spontaneous Fetal Death in Mice Deficient in Ethanolamine Kinase 2
Y Tian, P Jackson, C Gunter, J Wang, CO Rock, S Jackowski
The Journal of biological chemistry 2006
Effects of membrane and soluble EPCR on the hemostatic balance and endotoxemia in mice
X Zheng, W Li, JM Gu, D Qu, GL Ferrell, NL Esmon, CT Esmon
Blood 2006
Hughes Syndrome
MA Khamashta
2006
Anti-prothrombin IgG from patients with anti-phospholipid antibodies inhibits the inactivation of factor Va by activated protein C
M Galli, GM Willems, J Rosing, RM Janssen, JW Govers-Riemslag, P Comfurius, T Barbui, RF Zwaal, EM Bevers
British Journal of Haematology 2005
Diagnosis of antiphospholipid syndrome
ML Bertolaccini, MA Khamashta, GR Hughes
Nature Clinical Practice Rheumatology 2005
Inhibition of APC anticoagulant activity on oxidized phospholipid by anti–β2-glycoprotein I monoclonal antibodies
O Safa, CT Esmon, NL Esmon
Blood 2005
Antiphospholipid syndrome: multiple mechanisms
CG Mackworth-Young
Clinical & Experimental Immunology 2004
Current Debates in Antiphospholipid Syndrome: The Acquired Antibody-Mediated Thrombophilia
MA Öztürk, IC Haznedaroğlu, M Turgut, H Göker
Clinical and Applied Thrombosis/Hemostasis 2004
Antiphospholipid antibodies and pregnancy
M Galli, T Barbui
Best Practice & Research Clinical Haematology 2003
A thrombin-cross-reactive anticardiolipin antibody binds to and inhibits the anticoagulant function of activated protein C
KK Hwang, CD Yang, W Yan, JM Grossman, BH Hahn, PP Chen
Arthritis & Rheumatism 2003
Identification and characterization of a peptide mimetic that may detect a species of disease-associated anticardiolipin antibodies in patients with the antiphospholipid syndrome
S Visvanathan, JK Scott, KK Hwang, M Banares, JM Grossman, JT Merrill, J FitzGerald, RU Chukwuocha, BP Tsao, BH Hahn, PP Chen
Arthritis & Rheumatism 2003
Hypercoagulable state testing and malignancy screening following venous thromboembolic events
SR Deitcher, MP Gomes
Vascular medicine (London, England) 2003
Acquired activated protein C resistance, high tissue factor expression, and hyper-homocysteinemia in systemic lupus erythematosus
D Oh, SH Kim, MS Kang, NK Kim, NS Chang, BW Na, SY Chung, S Park, CS Cho
American Journal of Hematology 2003
Antiphospholipid/antiprotein antibodies, hemostasis-related autoantibodies, and plasma homocysteine as risk factors for a first early pregnancy loss: a matched case-control study
JC Gris, TV Perneger, I Quéré, E Mercier, P Fabbro-Peray, G Lavigne-Lissalde, M Hoffet, H Déchaud, JC Boyer, S Ripart-Neveu, ML Tailland, JP Daurès, P Marès, M Dauzat
Blood 2003
Low levels of activated protein C in patients with systemic lupus erythematosus do not relate to lupus anticoagulants but to low levels of factor II
MJ Simmelink, JA Fernandez, RH Derksen, JH Griffin, PG de Groot
British Journal of Haematology 2002
Suppressed intrinsic fibrinolytic activity by monoclonal anti-beta-2 glycoprotein I autoantibodies: possible mechanism for thrombosis in patients with antiphospholipid syndrome
R Takeuchi, T Atsumi, M Ieko, Y Amasaki, K Ichikawa, T Koike
British Journal of Haematology 2002
Laboratory diagnosis of the antiphospholipid syndrome
F Wisløff, EM Jacobsen, S Liestøl
Thrombosis Research 2002
The Antiphospholipid Syndrome II
M Ehrenfeld, H Amital, Y Shenfeld
The Antiphospholipid Syndrome II 2002
Factor V Leiden: a genetic risk factor for thrombotic microangiopathy in patients with normal von Willebrand factor–cleaving protease activity
TJ Raife, SR Lentz, BS Atkinson, SK Vesely, MJ Hessner
Blood 2002
NEW ASPECTS IN THE PATHOGENESIS AND TREATMENT OF THROMBOTIC THROMBOCYTOPENIC PURPURA AND HEMOLYTIC UREMIC SYNDROME
T Raife, R Montgomery
Reviews in Clinical and Experimental Hematology 2001
ANTIPHOSPHOLIPID ANTIBODIES AND THE COAGULATION CASCADE
E Anglés-Cano, MC Guillin
Rheumatic Disease Clinics of North America 2001
The role of tissue factor in the antiphospholipid syndrome
PM Dobado-Berrios, C L�pez-Pedrera, F Velasco, MJ Cuadrado
Arthritis & Rheumatism 2001
Acquired activated protein C resistance is associated with lupus anticoagulants and thrombotic events in pediatric patients with systemic lupus erythematosus
C Male, L Mitchell, J Julian, P Vegh, P Joshua, M Adams, M David, ME Andrew
Blood 2001
The Anticoagulant and Anti-inflammatory Roles of the Protein C Anticoagulant Pathway
CT Esmon
Journal of Autoimmunity 2000
Pathophysiology of the catastrophic antiphospholipid syndrome (CAPS)
DA Triplett, RA Asherson
American Journal of Hematology 2000
Use of the Dilute Russell Viper Venom Time (dRVVT): Its Importance and Pitfalls
DA Triplett
Journal of Autoimmunity 2000
Antiphospholipid Antibodies and the Protein C Pathway
NL Esmon, O Safa, MD Smirnov, CT Esmon
Journal of Autoimmunity 2000
Cardiolipin Enhances Protein C Pathway Anticoagulant Activity
JA Fernández, K Kojima, J Petäjä, TM Hackeng, JH Griffin
Blood Cells, Molecules, and Diseases 2000
Cardiolipin is a normal component of human plasma lipoproteins
H Deguchi, JA Fernandez, TM Hackeng, CL Banka, JH Griffin
Proceedings of the National Academy of Sciences 2000
Regulation of blood coagulation
CT Esmon
Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology 2000
Lipid Oxidation Enhances the Function of Activated Protein C
O Safa, K Hensley, MD Smirnov, CT Esmon, NL Esmon
The Journal of biological chemistry 2000
Dimers of β 2 -Glycoprotein I Mimic the in Vitro Effects of β 2 -Glycoprotein I-Anti-β 2 -glycoprotein I Antibody Complexes
BC Lutters, JC Meijers, RH Derksen, J Arnout, PG de Groot
The Journal of biological chemistry 2000
Competition of Annexin V and Anticardiolipin Antibodies for Binding to Phosphatidylserine Containing Membranes
GM Willems, MP Janssen, P Comfurius, M Galli, RF Zwaal, EM Bevers
Biochemistry 2000
Opposite β2-glycoprotein I requirement for the binding of infectious and autoimmune antiphospholipid antibodies to cardiolipin liposomes is associated with antibody avidity
CM Celli, AE Gharavi, H Chaimovich
Biochimica et Biophysica Acta (BBA) - Biomembranes 1999
Characterization of IgG monoclonal anti-cardiolipin/anti-beta2GP1 antibodies from two patients with antiphospholipid syndrome reveals three species of antibodies
M Zhu, T Olee, DT Le, RA Roubey, BH Hahn, VL Woods, PP Chen
British Journal of Haematology 1999
Clinical and laboratory manifestations of anti-factor V antibodies
TL Ortel
Journal of Laboratory and Clinical Medicine 1999
?2-glycoprotein I is necessary to inhibit protein C activity by monoclonal anticardiolipin antibodies
M Ieko, K Ichikawa, DA Triplett, E Matsuura, T Atsumi, KI Sawada, T Koike
Arthritis & Rheumatism 1999
The Effect of Membrane Composition on the Hemostatic Balance
MD Smirnov, DA Ford, CT Esmon, NL Esmon
Biochemistry 1999
Localization of the apoptosis-inducing activity of lupus anticoagulant in an annexin V-binding antibody subset
N Nakamura, T Ban, K Yamaji, Y Yoneda, Y Wada
Journal of Clinical Investigation 1998
LUPUS ANTICOAGULANTS AND ANTIPHOSPHOLIPID ANTIBODIES
P Thiagarajan, SS Shapiro
Hematology/Oncology Clinics of North America 1998
Binding of anticardiolipin antibodies to protein C via beta2-glycoprotein I (beta2-GPI): a possible mechanism in the inhibitory effect of antiphospholipid antibodies on the protein C system
T Atsumi, MA Khamashta, O Amengual, S Donohoe, I Mackie, K Ichikawa, T Koike, GR Hughes
Clinical & Experimental Immunology 1998
Many faces of lupus anticoagulants
DA Triplett
Lupus 1998
Methods for subtyping lupus anticoagulants
T Exner
Lupus 1998
Protein C Inhibitor Secreted from Activated Platelets Efficiently Inhibits Activated Protein C on Phosphatidylethanolamine of Platelet Membrane and Microvesicles
J Nishioka, M Ning, T Hayashi, K Suzuki
The Journal of biological chemistry 1998
A Chimeric Protein C Containing the Prothrombin Gla Domain Exhibits Increased Anticoagulant Activity and Altered Phospholipid Specificity
MD Smirnov, O Safa, L Regan, T Mather, DJ Stearns-Kurosawa, S Kurosawa, AR Rezaie, NL Esmon, CT Esmon
The Journal of biological chemistry 1998
Antiphospholipid Antibodies Accelerate Plasma Coagulation by Inhibiting Annexin-V Binding to Phospholipids: A “Lupus Procoagulant” Phenomenon
JH Rand, XX Wu, HA Andree, JB Ross, E Rusinova, MG Gascon-Lema, C Calandri, PC Harpel
Blood 1998
Differential Effects of Anti–β2-Glycoprotein I and Antiprothrombin Antibodies on the Anticoagulant Activity of Activated Protein C
M Galli, L Ruggeri, T Barbui
Blood 1998
Anti-inflammatory activity of cationic lipids
MC Filion, NC Phillips
British Journal of Pharmacology 1997
A SIMPLE PROCEDURE THAT INCREASES THE SPECIFICITY OF THE ACTIVATED PROTEIN C RESISTANCE TEST IN SAMPLES CONTAINING ANTIPHOSPHOLIPID ANTIBODIES
EM Jacobsen, F Wisløff
Thrombosis Research 1997
INFLUENCE OF THE PHOSPHATIDYLETHANOLAMINE (PE) AND BOVINE SERUM ORIGINS ON ANTI-PE ANTIBODY DETECTION BY ELISA
M Berard, MC Boffa
Thrombosis Research 1997
Les nouvelles cibles des anticorps ≪ antiphospholipides ≫
J Arvieux, L Darnige, F Sarrot-Reynauld
La Revue de Médecine Interne 1997
Cytokines, Adhesion Molecules, Antiendothelial Cell Autoantibodies and Vascular Disease
DC PhD, CS PhD
Cardiovascular Pathology 1997
Les “autres” anticorps antiphospholipides
M Sanmarco
Revue Française des Laboratoires 1997
Review : Abnormalities in the protein C anticoagulant pathway detected by a novel assay using human thrombomodulin
M Mohri, M Sata, K Gomi, Y Maruyama, M Osame, I Maruyama
Lupus 1997
THE LUPUS ANTICOAGULANT/ANTIPHOSPHOLIPID SYNDROME
SS M.D
Annual Review of Medicine 1996
False negative screening tests for lupus anticoagulants—An unrecognized problem?
EM Jacobsen, F Wisløff
Thrombosis Research 1996
Immunology of the antiphospholipid antibody syndrome
RA Roubey
Arthritis & Rheumatism 1996
The pathophysiology of alveolar osteonecrosis of the jaw: Anticardiolipin antibodies, thrombophilia, and hypofibrinolysis
R Gruppo, CJ Glueck, RE Mcmahon, J Bouquot, BA Rabinovich, A Becker, T Tracy, P Wang
Journal of Laboratory and Clinical Medicine 1996
Antiphospholipid Antibodies and Associated Clinical Manifestations
M Galli, G Finazzi, T Barbui
Hematology 1996
Functional Effects of Anticardiolipin Antibodies
EN Harris, SS Pierangeli
Lupus 1996
Protein C and other Cofactors Involved in the Binding of Antiphospholipid Antibodies: Relation to the Pathogenesis of Thrombosis
PG Groot, DA Horbach, RH Derksen
Lupus 1996
Immunology of antiphospholipid antibodies and their interaction with plasma proteins
DA Kandiah, SA Krilis
Lupus 1996
Non β 2 -Glycoprotein I Cofactors for Antiphospholipid Antibodies
M Galli
Lupus 1996
Impairments of the Protein C System and Fibrinolysis in Infection-Associated Stroke
RF Macko, SF Ameriso, A Gruber, JH Griffin, JA Fernandez, R Barndt, FP Quismorio, JM Weiner, M Fisher
Stroke; a journal of cerebral circulation 1996
Thrombogenic Properties of Murine Anti-Cardiolipin Antibodies Induced by β 2 Glycoprotein 1 and Human Immunoglobulin G Antiphospholipid Antibodies
SS Pierangeli, XW Liu, G Anderson, JH Barker, EN Harris
Circulation 1996
Activation of cultured vascular endothelial cells by antiphospholipid antibodies
R Simantov, JM LaSala, SK Lo, AE Gharavi, LR Sammaritano, JE Salmon, RL Silverstein
Journal of Clinical Investigation 1995
Autoantibodies
MH Lessof, SP Asper
American Heart Journal 1960

← Previous 1 2 3 4 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 1 policy sources
Posted by 1 X users
Referenced in 4 patents
14 readers on Mendeley
See more details